Form 4: Suvretta Capital and Affiliates Increase Stake in Benitec Biopharma Inc.
SEC Form 4 Filing
Suvretta Capital Management, along with affiliated funds and Aaron Cowen, report increased ownership in Benitec Biopharma Inc. through recent stock purchases.
Summary
- Suvretta Capital Management, LLC, along with Averill Master Fund, Averill Madison Master Fund, and Aaron Cowen, filed a Form 4 indicating changes in beneficial ownership of Benitec Biopharma Inc. common stock.
- On March 26, 2025, Averill Master Fund purchased 793,800 shares of Benitec Biopharma Inc. common stock at $13.00 per share.
- On the same date, Averill Madison Master Fund purchased 106,200 shares of Benitec Biopharma Inc. common stock at $13.00 per share.
- Following these transactions, Averill Master Fund beneficially owns 8,793,245 shares and Averill Madison Master Fund beneficially owns 1,066,764 shares.
- Suvretta Capital is the investment manager of the Funds, and Mr. Cowen may be deemed to control Suvretta Capital.
- Each of the Funds may be deemed a director by deputization by virtue of Kishan Mehta, a portfolio manager of Suvretta Capital, serving on the board of directors of the Issuer.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The increased investment suggests confidence, but it's a routine filing.
Positives
- Increased investment by Suvretta Capital and its affiliates may signal confidence in Benitec Biopharma's future prospects.
Industry Context
This filing reflects investment activity in the biopharmaceutical sector, where investment firms often take significant positions in companies with promising technologies or therapies.
Comparison to Industry Standards
- Comparing the investment size to similar biotech companies, the purchase represents a notable stake, potentially influencing Benitec Biopharma's strategic direction.
- Other comparable companies with similar market caps and investment profiles include [hypothetical company A] and [hypothetical company B], where institutional investors hold significant portions of shares.
Stakeholder Impact
- The increased investment could positively impact shareholder confidence.
- Employees may see this as a sign of stability and growth potential.
Key Dates
| Date | Description |
|---|---|
| 03/25/2025 | Date of the Securities Purchase Agreement between Benitec Biopharma Inc., Averill Master Fund, and Averill Madison Master Fund. |
| 03/26/2025 | Date of stock purchases by Averill Master Fund and Averill Madison Master Fund. |
| 03/28/2025 | Date of signature for the Form 4 filing. |
Keywords
Benitec Biopharma, Suvretta Capital Management, Averill Master Fund, Averill Madison Master Fund, Aaron Cowen, Beneficial Ownership, Form 4, Stock Purchase
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.